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Predicting and Monitoring Antiretroviral Adherence
Abstract
Antiretroviral therapy is complicated and can be hard to follow. For HIV-infected patients, adhering to a
prescribed regimen of antiretroviral therapy provides important individual survival benefits, and also
reduces the risk of developing drug resistant viral strains that can infect others. Even patients with initially
high levels of adherence to antiretroviral therapy face the challenge of maintaining those levels over time.
Ideally, clinicians caring for HIV-infected patients would have some way of predicting which patients are
most likely to need help in adhering to a prescribed regimen and an early warning system alerting them to
their patients’ non-adherence. This Issue Brief summarizes recent studies whose findings may help
clinicians predict and monitor their patients’ adherence before treatment failure occurs.
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Predicting and Monitoring Antiretroviral
Adherence
Editor’s Note: Antiretroviral therapy is complicated and can be hard to follow.
For HIV-infected patients, adhering to a prescribed regimen of antiretroviral
therapy provides important individual survival benefits, and also reduces the risk
of developing drug resistant viral strains that can infect others. Even patients
with initially high levels of adherence to antiretroviral therapy face the challenge
of maintaining those levels over time. Ideally, clinicians caring for HIV-infected
patients would have some way of predicting which patients are most likely to
need help in adhering to a prescribed regimen and an early warning system
alerting them to their patients’ non-adherence. This Issue Brief summarizes
recent studies whose findings may help clinicians predict and monitor their
patients’ adherence before treatment failure occurs.

Sustained antiretroviral adherence has been well-recognized as vital to HIV
treatment success. In patients just beginning therapy, the highest levels of
adherence (e.g., 95%) are associated with greatest chance of successful viral
suppression, and it is likely that similarly high levels are needed to maintain these
undetectable viral loads. However, in many patients adherence decreases over
time.
• Clinicians currently have little ability to detect declining adherence before the
clinical impact appears. Patients may be reluctant to admit that they are
missing doses, or may be unaware of the extent of their own non-adherence.
• Once virological rebound due to non-adherence occurs, it is often with
resistant virus. Improving adherence at that point may be too late for the
current regimen to still have treatment success.
• Detecting non-adherence before treatment failure provides an opportunity to
intervene. Identifying risk factors for non-adherence and methods for
monitoring adherence remains a research priority in HIV care.

Study examines the link
between ongoing
adherence and continued
treatment success

In one study, Dr. Gross and colleagues sought to determine the magnitude of
adherence needed to maintain HIV suppression, and whether pharmacy refill
data could be used to predict treatment failure.
• The investigators studied a population of HIV-infected patients in British
Columbia, Canada, which has a well-established database for tracking
patients’ antiretroviral use and clinical status. The study included adults who
had started antiretroviral therapy between August 1996 and September 2003,
and had successfully achieved undetectable viral loads at some point.
• The study used pharmacy data to track adherence. Adherence was defined as
days’ supply of medication dispensed divided by the days between prescription
refills.
• The study included 1,634 adults who had started triple combination
antiretroviral therapy, achieved HIV suppression, and refilled their
prescriptions at least three times after suppression was confirmed. Patients
were followed until September 2004.

Adherence, measured by
refill data, predicts failure
to maintain HIV
suppression

The study found that high levels of adherence required for maintaining HIV
suppression are similar to the levels needed to achieve suppression. But even
below the 95% threshold, greater adherence was associated with continued
treatment success.
• Overall, adherence was high, with 84.4% of the patients having greater than
95% adherence over the observed period, which was a median of 29 months.
• A total of 606 patients (37.1%) experienced “virological rebound” or
treatment failure, with a median time to treatment failure of 22 months.
• After adjusting for other demographic and clinical factors, patients with 95%
adherence or less, as measured by pharmacy refill data, were 1.66 times more
likely to experience treatment failure than those with greater than 95%
adherence.
• As adherence decreased, treatment failure increased. Overall, 34% of patients
with greater than 95% adherence had virological rebound, compared to 41%
of those with 70%-95% adherence, and 63% of those with less than 70%
adherence.

Non-adherence is
detectable three months
before treatment failure

In a prospective, observational study, Gross and colleagues followed 116 patients
for one year to determine if suboptimal adherence can be identified prior to
treatment failure during a period of HIV suppression. They measured adherence
with microelectronic monitors on medication bottle caps that record when the
bottle is opened.
• Patients were recruited from five HIV clinics in Philadelphia from May 2000
to August 2004. The patients were predominantly male, poor, and AfricanAmerican.

• Only 52% of patients were fully adherent (defined as adherence levels of at
least 95%). Over the course of the year, 7 of 116 patients experienced
virological rebound. In the three months before treatment failure, this group
had a median adherence of 38%, compared to 96% adherence for the group
that maintained viral suppression.
• These differences in adherence levels were detectable at 30 days, 60 days, and
90 days before treatment failure occurred.

Financial worries strongly
predict poor adherence

In a separate analysis of the same 116 patients, Holmes, Gross, and colleagues
examined whether baseline measures of patients’ quality of life could predict
adherence over time. They considered different aspects of HIV-related quality of
life, including overall functioning, sexual function, health worries, medication
worries, life satisfaction, and trust in the HIV care provider. The investigators
also accounted for an array of sociodemographic and substance use
characteristics.
• Compared to patients with at least 95% adherence, patients with poor
adherence were more likely to have used alcohol in the past year. Alcohol use
has been one of the most consistently identified predictors of antiretroviral
adherence in other studies.
• After adjusting for other factors, financial worries were strongly associated
with poor adherence. Financial worries included concerns about living on a
fixed income, how to pay bills, and having too little money to take care of
oneself.
• No other aspect of quality of life was associated with subsequent adherence.

POLICY IMPLICATIONS

These results reinforce the importance of ongoing attention to adherence in the
care of HIV patients and highlight promising strategies for early identification of
suboptimal adherence.
• Clinicians should recognize that there can be a considerable time lag between
poor adherence and treatment failure. Even in patients maintaining viral
suppression, clinicians should reinforce the need for continued adherence.
• Incorporating a refill-based measure of adherence into clinical practice may
allow real-time monitoring of adherence and an opportunity for intervention.
Consideration should be given to automating this measure and providing it to
clinical care teams as an early warning system. This strategy is ripe for testing
in a clinical trial.
• Questions about financial worries may be useful as a way to identify patients
at higher risk for adherence problems. If further research confirms these
findings, financial worries should be addressed in behavioral interventions
designed to improve retroviral adherence.
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